Extension of Maturity Date of 2017 Note and Operational Update

by David | May 4, 2020 | Press Releases

BOSTON and SYDNEY — 4 May 2020 — GI Dynamics® Inc. (ASX:GID) (“GID” or the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, provides the following update regarding its operations and financing....

GI Dynamics Announces Change to Board of Directors

by David | Mar 30, 2020 | Press Releases

BOSTON and SYDNEY — 30 March 2020 — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, announces today that Timothy Barberich resigned as a non-executive director of its Board of...

Joint International Consensus Statement for Ending Stigma of Obesity

by David | Mar 4, 2020 | Publications & Abstracts

People with obesity commonly face a pervasive, resilient form of social stigma. They are often subject to discrimination in the workplace as well as in educational and healthcare settings. Research indicates that weight stigma can cause physical and psychological...

Appointment of Director

by David | Mar 2, 2020 | Press Releases

BOSTON and SYDNEY — 2 March 2020 — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce that it has increased the size of the Board from four to five directors and...

BioWorld

by David | Jan 28, 2020 | GID In the Media, Publication Media

GI Dynamics enrolls first patient in pivotal EndoBarrier trial

First Patient Enrolled in the US STEP-1 Clinical Trial of EndoBarrier at Michigan Medicine

by David | Jan 27, 2020 | Press Releases

BOSTON and SYDNEY — 28 January 2020 — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce the first patient in the United States (U.S.) STEP-1 clinical trial has...

EndoBarrier Study Shows Improvement in Cardiovascular Risk

by David | Jan 14, 2020 | Press Releases

BOSTON and SYDNEY — 15 January 2020 — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce positive EndoBarrier data from the University of Freiburg in Germany...

Confirmation of Funding of 2019 Note and Issuance of Warrants

by David | Jan 14, 2020 | Press Releases

BOSTON and SYDNEY — 14 January 2020 — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce that further to its announcements of 22 August 2019, 6 December 2019, 9...

The United Kingdom’s first NHS Endobarrier service for advanced diabesity: 1-year outcomes for all 62 treated patients

by David | Jan 7, 2020 | Publications & Abstracts

EndoBarrier was highly effective in this setting in patients with advanced diabetes and obesity. Given the high cardiovascular and microvascular risk of these patients, benefits might outweigh risks. As an endoscopic procedure it is relatively simple and non-invasive....

Michigan Health Lab

by David | Jul 8, 2019 | GID In the Media, Publication Media

Minimally-Invasive, Innovative Therapy Used for Treating Type 2 Diabetes and Obesity U-M expert discusses an upcoming clinical trial involving a new non-invasive, endoscopic weight-loss procedure called the EndoBarrier®.